You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

Happy Wednesday, Zingernation! Half days used to mean getting home from school early and scoring some extra Xbox time before my mom got home. Now, it means the market closes at 1:00 pm ET and I have less time to trade 0DTE options.

–Aaron Bry & Nic Chahine

Today’s Price Action:

$SPY: +.45%
$QQQ: +.83%
$DIA: -.12%

Plus, you need solid information and quick news to be successful at trading. And now you can get that with Benzinga Pro for 50% off.

TODAY’S MOST VOLATILE STOCKS

TODAY’S TOP STORY

June Jobs Report Preview: Cooling Labor Market Trends May Further Bolster Rate Cut Hopes

What Happened: The U.S. labor market doesn’t appear as tight and hot as a couple of months ago, with the June’s Employment Situation report likely to show an overall cooling trend from a very strong performance in May.

Basically: Slated for release Friday at 8:30 a.m. ET, the official jobs report from the Bureau of Labor Statistics is expected to reveal a decline in nonfarm payroll growth and a slowdown in earnings momentum.

So: On Tuesday, Fed Chair Jerome Powell suggested the labor market is “cooling off appropriately,” and the Fed will monitor these developments, ready to act if conditions warrant. Here is what economists are expecting for the big jobs report due Friday.

PRESENTED BY BENZINGA

Get 50% Off Benzinga Pro for July 4th 🇺🇸

For a limited time, you can get the platform trusted by over 6,000 traders, including Wall Street pros, at half the price. Claim your 50% discount.

FIVE MOVERS

Amazon shares fell today as Jeff Bezos sells more shares, potentially gearing up for a purchase of an NFL team.

Novo Nordisk shares fell as fears mount regarding potential adverse side effects from weight-loss drugs like Ozempic.

Robinhood shares closed higher today following the recent acquisition of Pluto Capital, an AI-powered research firm.

Broadcom shares soared higher today after Nancy Pelosi disclosed call options in the semiconductor play.

Avid Bioscience’s stock closed higher today after the company reported strong earnings and revenue above estimates.

ONE TRADE IDEA FOR FRIDAY

This Oil And Gas Company Has 'Top-Tier Cost Structure, Strong Operational Performance': Analyst

Briefly: Shares of Permian Resources Corp climbed in early trading on Wednesday. The company's increased Delaware footprint and strong M&A track record should support continued organic and inorganic growth, according to BMO Capital Markets.

Basically: The Permian Resources Analyst: Phillip Jungwirth upgraded the rating for Permian Resources from Market Perform to Outperform, while keeping the price target unchanged at $21.

The Permian Resources Thesis: The company has a large-scale and low-cost footprint in Delaware, Jungwirth said in the upgrade note. Here’s why the analyst expects the stock to outperform peers.

PRESENTED BY STARPAX

A New Cancer Treatment Conceived To Do What No Other Cancer Treatments Can

Current cancer treatments struggle to reach 90% of the tumor volume. Antibodies, nanocarriers, precision targeting medicine, and even immune cells, don’t reach more than 10% of the tumor volume. Join us in our mission to change the way we treat cancer. 

Here's why you should consider investing in Starpax’s patented technology:

• The future of cancer treatment is here: Starpax's cutting-edge technology features Starpax Living self-propelled Magnetodrones^TM, which are sensitive to special magnetic fields and carry drugs on their surface to the tumor volume. 

• Cutting-edge technology: The Living Magnetodrones, guided by the PolarTrak’s artificial intelligence, are injected directly into the tumor. Preclinical trials have demonstrated a 100% remission rate in extremely aggressive tumors without any side effects observed.

• Reduced risk, accelerated progress: Starpax minimizes trial risks and accelerates approvals with our FDA-approved anti-cancer molecules that can target six common cancers simultaneously. We meet the criteria for the FDA Fast Track Program and Health Canada accelerated review standards.

• Scalable business model: Partnering with top U.S. firms, Starpax plans rapid deployment of 25 treatment centers within seven years, with forecasted EBITDA reaching $12 billion annually upon FDA approval.
  

Invest in Starpax today and be part of this transformative journey.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Where we highlight the movers and the losers, the upgrades and the downgrades, the top stories and opportunities in the trillion dollar REIT and real asset industry. Subscribe here.

Mining Weekly: Get an insider's edge with news, analysis, and commentary on what’s shaping the mining and commodities industry that powers the global economy. Subscribe here.